Apoptosis in cancer: from pathogenesis to discovery of advanced selective Bcl-2 family inhibitors | ||||
| Archives of Pharmaceutical Sciences Ain Shams University | ||||
| Article 4, Volume 3, Issue 1, January 2019, Page 37-54 PDF (1.02 MB) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/aps.2019.20225 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Samaa Abbas  1; Nermin S. Abdou 2; Deena S. Lasheen3; Dalal A. Abou El Ella4
| ||||
| 1Pharmaceutical Chemistry, Faculty of Pharmacy, ASU, Cairo, Egypt | ||||
| 2Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt | ||||
| 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo11566, Egypt | ||||
| 4Pharmaceutical Chemistry Department, Faculty of Pharmacy, El-Nahda University, Beni sweif, Egypt | ||||
| Abstract | ||||
| Cancer is a genetic disease characterized by two features: unregulated cell growth and tissue invasion (metastasis). It can be viewed as the result of a succession of genetic changes during which a normal cell is transformed into a malignant one. Evasion of cell death, apoptosis, is one of the essential changes in a cell that cause this malignant transformation. Hence, reduced apoptosis or its resistance plays a vital role in carcinogenesis. The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway. Disease states arise upon deregulation of the Bcl-2 family of proteins, where cell death is either promoted or evaded; one of the most common tactic cancer cells utilize to promote survival is anti-apoptotic protein overexpression. Specifically, Bcl-2 overexpression has been shown to be a major chemoresistance factor in a number of human cancers, and for this reason, Bcl-2 targeting is a pharmacologic priority in the quest to reactivate cell death for therapeutic benefit in cancer. | ||||
| Keywords | ||||
| apoptosis; Bcl-2; Extrinsic pathway; Intrinsic pathway; Caspase; BH3 | ||||
| References | ||||
|
1. Robert G, Fenton Dan I, longo. Harrison’s hematology and oncology chapter 24: cancer cell biology and angiogenesis. 2010.
3. Mohan H. Textbook of pathology. 5 edition. New Delhi: Jaypee Brothers Medical Publishers. 2010; 21-60.
4. Merkle CJ. Cellular adaptation, injury, and death. In pathophysiology: concepts of altered health states. Eight editions. Edited by: Porth CM, Matfin G. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins. 2009; 94-111.
5. Abou-Ghali M, Stiban J. regulation of Ceramide Channel Formation and disassembly: Insights on the Initiation of Apoptosis. Saudi Journal of Biological Sciences. 2015.
6. Kumar V, Abbas AK, Fausto N, Aster JC. Robins and Cotran: pathologic basis of disease. 8 edition. Philadelphia: Saunders Elsevier. 2010; 25-32.
7. Hengartner MO. Apoptosis: corralling the corpses. Cell. 2000; 104:325-328.
8. Vaux D, Silke J. mammalian mitochondrial IAP-binding proteins. Biochem Biophys Res Commun. 2003; 203:449-504.
9. lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest. 2005; 115:2665-2672.
10. O’Brien MA, Kirby R. Apoptosis: disease. J Vet Emerg Crit Care. 2008; 18:572-585.
11. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv. 2000; 74:281-286.
12. Karp G. Cell and molecular biology: Concepts and experiments. 5 edition. John New Jersey. Wiley and Sons. 2008; 653-657.
13. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116(2):205-219.
14. Kroemer G, Galluzzi I, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87:99-163.
15. Lacasse EC, Mahoney DJ, Cheung HH, Pichette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008; 27:6252-6275.
16. Tsujimoto Y, finger IR, Yunis J, Nowell PC, Croce CM. The chromosome breakpoint of neoplastic B the t (14; 18) chromosome translocation. Science 1984; 226:1097-1099.
17. Reed JC. BCl-2 family proteins: apoptosis and chemoresistance in haematologic malignancies. Semin Haematol. 1997; 34:9-19.
18. Ghobrial IM, Witzig TE, Adjei AA. Targeting in cancer therapy. CA Cancer J Clin. 2005; 55:178-194.
19. Hanahan D, Weinberg RA The hallmarks of cancer. Cell. 2000; 100:57-70.
20. Rebecca SY. Apoptosis in cancer: from pathogenesis to treatment. Wong Journal of Experimental & Clinical Cancer Research. 2011; 30:87.
21. lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci. 2005; 118:265-267.
22. Levine AJ, Momand J, finlay CA. The p53 tumor suppressor gene. Nature. 1991; 351(6326):453-456.
23. Bai l, Zhu WG. p53: structure, function, and therapeutic applications. J Cancer Mol. 2006; 2:141-153.
24. Oren M, Rotter V. Introduction: p53–the first twenty years. Cell Mol Life Sci. 1999; 55:9 11.
25. Iane DP. p53, guardian of the genome. Nature. 1992; 358:15-16.
26. Fink SI, Cookson BT. Apoptosis, pyroptosis, and necrosis: eukaryotic cells. Infect Immun. 2005; 73:1907-1916.
27. Lacasse EC, Mahoney DJ, Cheung HH, Pichette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008; 27:6252-6275.
28. Wei Y, Fan T, Yu M., and apoptosis. Acta Biochim Biophys Sin. 2008; 40:278-288.
29. Gross A, McDonnell JM, Korsmeyer SJ. BCl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999; 13:1899-1911.
30. Minn AJ, Vélez P, Schendel SI, Liang H, Muchmore SW, Fesik SW, fill M, Thompson CB. BCl-x (I) ion channel in synthetic Lipid membranes. Nature. 1997; 385(6614):353-357.
31. Dawson G, Kluc RM. BCl-2 family-regulated apoptosis in health and disease. Cell Health and Cytoskeleton. 2010; 2:9-22.
32. Youle RJ, Strasser A. The BCl-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008; 9:47-59.
33. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M. BCl-XI-Bak peptide complex: regulators of apoptosis. Science. 1997; 275 (5302):983-986.
34. Chen H-C, Kanai M, Inoue-Yamauchi A, Tu H-C, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM. Of cell death regulation by the BCl-2 family. Nat Cell Biol. 2015; 17:1270-1281.
35. Luna-Vargas MPA, Chipuk JE. physiological control of BAK, BAX, and beyond. Trends Cell Biol. 2016; 26:906-917.
36. Wei MC, Zong WX, Cheng EH, lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a dysfunction and death. Science. 2001; 292:727-730.
37. Thomas P, Andrea l, Denis ER, Adam Z, Evripidis G. Progress in targeting the BCl-2 family of proteins. Current Opinion in chemical biology. 2017; 39:133–142.
38. Kim R, Emi M, Matsuura K, Tanabe K. Antisense and nonantisense effects of anti-sentence-2 roles of BCl-2 cancer therapy. CancerGene Ther. 2007; 14:1-11.
39. O’Brien S, Moore JO, Boyd TE. 5-Year survival or refractory chronic lymphocytic Leukemia in a randomized, without oblimersen. J Clin Oncol. 2009; 27:5208-12.
40. Vogler M, Dinsdale D, Dyer, and Cohn GM. Review: BCl-2 inhibitors: with big cancer therapy. Cell Death and Diff. 2009; 16:360-367.
41. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass l, Murthy Madiraju SR, Goulet D, Viallet J, Be´ lec I, Billiot X. Small molecule obatoclax (GX15-070) antagonizes MCl-1 and overcomes MCl-1-mediated resistance to apoptosis. Proc Nati Acad Sci U S A. 2007; 104:19512-19517.
42. Hwang JJ, Kuruvilla J, Mendelson D. Phase l studies of obatoclax (GX15-070), a small molecule pan-BCl-2 family antagonist, in patients with advanced solid tumorsorlymphoma. Clin Cancer Res. 2010; 16: 4038-45.
43. Pascuzzi I, Gonen M, Gardner JR. Targeting BCl-2 with the BH3 mimetic AT-101 markedly enhances the agents in vitro and in vivo models of B-cell lymphoma. Blood. 2008; 111:5350-eight.
44. Wang G, Nikolova-Coleska Z, Yang CY. Structure-based designofpotentsmall-moleculeinhibitorsofanti- apoptotic BCl-2proteins. JMedChem. 2006; 49:6139-42.
45. Oltersdorf T, Elmore SW, Shoemaker AR. An inhibitor of BCl-2 induces regression of solid tumors. Nature. 2005; 435:677–681.
46. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M Deckwerth Tl, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, ltai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of BCl-2 of solid tumors. Nature. 2005; 435:677-681.
47. Tse C, Shoemaker AR, Adickes J. ABT-263. an orally bioavailable BCl-2 family inhibitor. Cancer Res. 2008; 68:3421–3428.
48. Wong. Apoptosis in cancer: from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research. 2011; 30:87.
49. Khan KH. Cancer Therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol/Hematol. 2014.
50. Bai l, Chen J, McEachern D, Liu l, Zhou H, Aguilar A, Wang S. BM-1197: a novel and specific BCl-2/Bcl-XI Song-lasting tumor regression in vivo. PLoS ONE. 2014; 9:e99404.
51. Ne´ mat F, de Montrion C, Yang G, Kraus-Berthier I, Carita G, Sastre-Garau X, Berniard A, Vallerand D, Geneste O, de Pieter l. Targeting BCl-2/Bcl-XI patient-derived xenografts. PLoS ONE. 2014; 9:e80836.
52. The anti-apoptotic BCl-2 and BCl-XI, treatment of cancer (AZD4320). 250th ACS Annual Meeting. 2015.
53. Souers AJ, Leverson JD, Boghaert ER. ABT-199, a potent and selective BCl-2 inhibitor, achieves antitumor activity while sparing patients. Nat Med. 2013; 19:202–208.
54. Salem AH, Agarwal S, Dunbar M. Low and High Fat Meals on the Pharmacokinetics of Venetoclax, a selective first-in-Class BCl-2 Inhibitor. J Clin Pharmacol. 2016.
55. Casara P, Davidson J, Cameron A, Ie Toumelin-Braizat G, Vogler M. S55746 novel orally active BCl-2 potent inhibitor that tumor growth. Oncotarget, Impact journals. 2018; 9:20075-20088.
56. Messene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, Coleman PM, Deshayes K, Fairbrother WJ. Structure-guided design of a selective BCl-X (I) inhibitor. Nat Chem Biol. 2013; 9:390-397.
57. Tao Z-F, Hasvold I, Wang I, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM. Discovery of a potent and selective BCl-XI in vivo activity. ACS Med Chem Lett. 2014; 5:1088-1093.
58. Iverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont ID, Nimmer P, Xiao Y, Ma XM. exploiting selective BCl-2 to dissect cell survival dependencies and cancer therapy. Sci Transl Med. 2015; 7:279ra40.
59. Lee EF, Czabotar PE, Yang H, Sleebs BE, Messene G, Colman PM, Smith BJ, Fairlie WD. conformational changes in BCl-2 pro-survivall their capacity to bind ligands. J Biol Chem. 2009; 284:30508-30517.
60. fire E, Gulla´ SV, Grant RA, Keating AE. Mcl-1-Bim minor structural changes. Protein Sci. 2010; 19:507-519.
61. Doi K, li R, Sung S-S, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X. Discovery of marinopyrrole A (navitoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012; 287:10224-10235.
62. AbiWord F, Xiao C, Liu M, Azmi AS, Aboukameel A, Mady ASA, Gulappa T, Cierpicki T, Owens S, Zhang T. An inhibitor of mcl-1 and in vivo. Mol Cancer Ther. 2014; 13:565-575.
63. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y. Selective small-molecule MCl-1 on-target cancer cell in combination with ABT-263 (navitoclax). Cell Death Dis. 2015; 6:e1590.
64. Lee T, Bian Z, Zhao B, Hogdal IJ, Sensintaffar JI, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N. biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017; 591:240-251.
65. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno Al, le Toumelin-Braizat G, Chanrion M, Kelly Gl, Gong J-N, Moujalled DM. The MCl1 inhibitor S63845 is tolerable and diverse cancer models. Nature. 2016; 538:477-482.
67. Berger S, Procko E, Margineantu D, Lee EF, Shen BW, Zetter A, Silva D-A, Chawla K, Herold MJ, Garnier J-M. high specificity the roles of BCl2 in cancer. Elife. 2016; 5.
68. Han B, Park D, li R, Xie M, Owonikoko TK, Zhang G, Sica Gl, Ding C, Zhou J, Magis AT. Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell. 2015; 27:852- 863.
69. Song T, Wang Z, Ji F, Feng Y, Fan Y, Chai G, Li X, Li Z, Zhang Z. Deactivation of Mcl-1 by dual-function small-molecule inhibitors targeting the BCl-2 homology 3 domain and facilitating Mcl-1 ubiquitination. Angew Chem Int Ed Engl. 2016; 55:14250-14256.
70. Lee S, Wales TE, Escudero S, Cohen DT, Zuccarelli J, Gallagher CG, Cohen NA, Huhn AJ, Bird GH, Engen JR. Allosteric inhibition of antiapoptotic MCl-1. Nat Struct Mol Biol. 2016; 23:600-607.
71. Akc¸ ay G, Belmonte MA, Aquila B, Chuaqui C, Hird AW, lamb Ml, Rawlins PB, Su N, Tentarelli S, Grimster NP. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain. Nat Chem Biol. 2016; 12:931-936.
| ||||
|
Statistics Article View: 874 PDF Download: 757 |
||||
